The subcellular localization of vaccinia‐related kinase‐2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
VRK is a new kinase family of unknown function. Endogenous human vacinia‐related kinase 2 (VRK2) protein is present in both the nucleus and the cytosol, which is a consequence of alternative splicing of two VRK2 messages coding for proteins of 508 and 397 amino acids, respectively. VRK2A has a C‐terminal hydrophobic region that anchors the protein to membranes in the endoplasmic reticulum (ER) and mitochondria, and it colocalizes with calreticulin, calnexin and mitotracker; whereas VRK2B is detected in both the cytoplasm and the nucleus. VRK2A is expressed in all cell types, whereas VRK2B is expressed in cell lines in which VRK1 is cytoplasmic. Both VRK2 isoforms have an identical catalytic N‐terminal domain and phosphorylate p53 in vitro uniquely in Thr18. Phosphorylation of the p53 protein in response to cellular stresses results in its stabilization by modulating its binding to other proteins. However, p53 phosphorylation also occurs in the absence of stress. Only overexpression of the nuclear VRK2B isoform induces p53 stabilization by post‐translational modification, largely due to Thr18 phosphorylation. VRK2B may play a role in controlling the binding specificity of the N‐terminal transactivation domain of p53. Indeed, the p53 phosphorylated by VRK2B shows a reduction in ubiquitination by Mdm2 and an increase in acetylation by p300. Endogenous p53 is also phosphorylated in Thr18 by VRK2B, promoting its stabilization and transcriptional activation in A549 cells. The relative phosphorylation of Thr18 by VRK2B is similar in magnitude to that induced by taxol, which might use a different signalling pathway. In this context, VRK2B kinase might functionally replace nuclear VRK1. Therefore, these kinases might be components of a new signalling pathway that is likely to play a role in normal cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
DNA damage induces phosphorylation of the amino terminus of p53
Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997) · Genes & Development · doi:10.1101/gad.11.24.3471 · Cited by 818
'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
Regulation of p53 function and stability by phosphorylation.
Ashcroft, M., Kubbutat, M. H. G., & Vousden, K. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1751 · Cited by 452
Webley, K., Bond, J. A., Jones, C. J., Blaydes, J. P., Craig, A., Hupp, T., & Wynford-Thomas, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2803-2808.2000 · Cited by 192
Cited by
DNA Cross-Bridging Shapes a Single Nucleus from a Set of Mitotic Chromosomes
Samwer, M., Schneider, M. W. G., Hoefler, R., Schmalhorst, P. S., Jude, J. G., Zuber, J., & Gerlich, D. W. (2017) · Cell · doi:10.1016/j.cell.2017.07.038 · Cited by 237
“This might be driven by nuclear import of VRK1, or by the related kinase VRK2, which resides in the NE (Blanco et al., 2006; Nichols et al., 2006).”
BackgroundDownregulation of VRK1 by p53 in Response to DNA Damage Is Mediated by the Autophagic Pathway
Valbuena, A., Castro-Obregón, S., & Lazo, P. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017320 · Cited by 66
“VRK1, pCEFL-HA-VRK1(K179E) [18,23], pCEFL-HA-VRK2A and pCEFL-HA-VRK2B [34].”
ResultSelf-citationVRK1 is a synthetic-lethal target in VRK2-deficient glioblastoma
Shields, J. A., Meier, S. R., Bandi, M., Mulkearns-Hubert, E. E., Hajdari, N., Ferdinez, M. D., Engel, J. L., Silver, D. J., Shen, B., Zhang, W., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4443 · Cited by 60
“The functional role of VRK2 is less clear, however, it has been reported to downregulate apoptosis via direct interaction with antiapoptotic protein Bcl-xL and by downregulating proapoptotic Bax (10). p53 and BAF have also been reported as substrates for VRK2 (11, 12).”
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system
So, J., Mabe, N. W., Englinger, B., Chow, K.-H., Moyer, S. M., Yerrum, S., Trissal, M. C., Marques, J. G., Kwon, J. J., Shim, B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158755 · Cited by 45
“It has been shown to share substrates with VRK1, namely p53 (28).”
Metadata
- Authors
- Blanco, S., Klimcakova, L., Vega, F. M., & Lazo, P. A.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2006-05-08
- Volume
- 273
- Issue
- 11
- Pages
- 2487-2504
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W1533409351
- Cited by
- 97
- References
- 11
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The subcellular localization of vaccinia‐related kinase‐2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. https://app.cochat.ai/papers/10.1111/j.1742-4658.2006.05256.x
- The paper
- Blanco, S., Klimcakova, L., Vega, F. M., & Lazo, P. A. (2006). The subcellular localization of vaccinia‐related kinase‐2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. The FEBS Journal. https://doi.org/10.1111/j.1742-4658.2006.05256.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.